Alzheimer’s Disease Diagnostics Market: By Diagnostic Techniques, By Type, By End Use, and Region Forecast 2020-2031

Alzheimer’s Disease Diagnostics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Diagnostic Techniques (Biomarker, CSF Biomarker, blood- Based Biomarker, Imaging Technique, Genetic Testing, Cognitive Assessment Tests), By Type (Triage, Diagnosis, Screening), By End Use (Hospitals, Diagnostic Laboratories, Academic & Research Institutes), and Region Forecast 2020-2031

Alzheimer’s Disease Diagnostics Market size was valued at US$ 5.2 billion in 2024 and is projected to reach US$ 9.1 billion by 2031, growing at an 8.1% from 2025–2031. Moreover, the U.S. Alzheimer’s Diagnostics Market is projected to grow significantly, reaching an estimated value of US$ 3,600 million (US$ 3.6 billion) by 2031.

The market is poised at the intersection of clinical demand and technological advancement. With the world's population growing older, early and precise diagnosis of Alzheimer's disease is becoming an imperative rather than a decision. Diagnosis has moved beyond clinical observation to utilizing sophisticated tools such as PET imaging, cerebrospinal fluid biomarkers, and AI-based cognitive tests. What was once a slow and uncertain process is being re-scripted by precision medicine, making intervention on time and better-informed care planning possible. This shift is not merely technical it's deeply human. It's a move away from reactive care and toward proactive understanding, giving people and families a longer window of time to adapt, respond, and live with dignity.

The course of this sector appears to be one of increased cooperation between pharma, diagnostic companies, and tech entrepreneurs looking for non-invasive, scalable, and affordable diagnostic machines. Liquid biopsies and panels of blood-based biomarkers—formerly in the realm of experimentation—are now moving to clinical trials with real-world applications. Regulators are beginning to move faster to approve new test platforms, and even payers are demonstrating early signs of coverage for pre-symptomatic testing. These advancements aren't only shaping the market; they're upsetting the conventional care continuum. As early-stage detection becomes the norm and not the exception, Alzheimer's diagnosis is transforming from a specialist research issue to an integral component of neurological care systems globally.

Facts & Figures

  • The median time from onset of symptoms to definitive diagnosis of Alzheimer's disease remains more than 2.5 years worldwide, representing delays in diagnosis and suboptimal use of early testing assays-considering the added publicity.
  • In clinical trials, minimally invasive blood-based biomarker tests such as phosphorylated tau (p-tau) assays had more than 85% concordance with PET imaging, a paradigm-shifting transition toward minimally invasive diagnostics.
  • More than 20 AI systems are under trial to help diagnose Alzheimer's diverse including speech pattern analysis, online cognitive testing, and computer-aided neuroimaging interpretation
  • Higher numbers of U.S. and EU payors are demonstrating early diagnosis reimbursement for Alzheimer's, particularly blood and cognitive tests, under mounting pressure to intervene early and limit healthcare expenditure.

Key Developments

  • In May 2025, The FDA approved marketing of the first-ever blood-based in vitro diagnostic to aid Alzheimer's diagnosis: the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio. The test is a major step forward toward early, non-invasive detection of amyloid plaque buildup in symptomatic patients age 55 and older.
  • In April 2025, Labcorp launched its national pTau-217/Beta Amyloid 42 Ratio test as part of its menu of Alzheimer's blood biomarkers. The test enables more scalable, earlier-stage detection of Alzheimer's in outpatient and ambulatory care settings.
  • In April 2025, Lantheus Holdings announced that its clinical-stage PET imaging drug candidate MK-6240 (F18-florquinitau) met significant endpoints in milestone trials. Such success paves the way for a pending New Drug Application (NDA) filing with the FDA in Q3 2025.

Alzheimers Disease Diagnostics Market Segmentation

Based on the Diagnostics Technique

  • Biomarkers
    • CSF Biomarkers
    • Blood-Based Biomarkers
  • Imaging Techniques
  • Genetic Testing
  • Cognitive Assessment Tests

Among the new diagnostic tools, blood-based biomarkers are revolutionizing the affordability and availability of Alzheimer's testing. Unlike cerebrospinal fluid sampling or imaging, these tests draw from easily accessible blood samples to measure first pathological changes e.g., beta-amyloid and phosphorylated tau levels with the result of being able to screen on a routine basis even in non-specialist centers. Their very minimally invasive character eliminates the psychological and logistical hurdles commonly linked to conventional diagnostics. In addition, their scalability matches the growing focus on early population-level screening. Laboratories and firms are competing to bring these tests to market, aided by favourable trial outcomes and regulatory fast-track mechanisms. With precision medicine development, diagnostics based on blood will be the foundation of Alzheimer's risk assessment and disease surveillance.

Based on the type

  • Triage
  • Diagnosis
  • Screening

The diagnostic segment commands the Alzheimer's diagnostics market based on clinical demand for precise, stage-specific diagnosis of the disease. Unlike screening or triage, which is initial, diagnostic devices affirm the presence and progression of Alzheimer's through a combination of imaging, mental status examination, and biomarker testing. Hospitals and specialty clinics utilize this level to create patient-specific treatment plans, address comorbidities, and trigger proper caregiver planning. The arrival of novel therapeutics and disease-altering drugs has placed precise diagnosis in the spotlight. Payors and regulatory bodies are ever more making coverage decisions based on confirmed diagnostic markers, even more positioning this segment as the cornerstone to the entire diagnostic process.

Based on the end user

  • Hospital
  • Diagnostic Laboratories
  • Academic and Research Institutes

Hospitals represent the most important end-use environment for diagnosing Alzheimer's, in large part because they contain the entire array of test technology—MRI, PET, blood tests, and neuropsychology staff—all under one roof. Multidisciplinary geriatrics and neuroscience teams will be in a better position to unravel difficult results and orchestrate what comes next. For most patients, hospitals also are the initial point of contact after cognitive decline, putting them at the front of timely care. Also, hospital funding and teaching affiliations enable the hospitals to be involved in clinical trials for new diagnostic technology, and they become privy to innovative solutions ahead of the curve. As early diagnosis becomes the norm, hospitals are in a dual role: first-line caregivers and research centres for Alzheimer's diagnosis.

Alzheimers Disease Diagnostics Market Summary

Study Period

2025-2031

Base Year

2024

CAGR

8.1%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific

Alzheimer’s Disease Diagnostics Market Dynamics

Drivers

One of the strongest drivers of the Alzheimer's diagnostics market is the extremely high rate of growth in the incidence of dementia across the globe, especially among the elderly. When life expectancy rises, particularly in the developed and emerging nations, the risk pool for Alzheimer's grows accordingly. The World Health Organization estimates that more than 55 million individuals currently have dementia, and this number will double roughly every 20 years. This demographic condition imposes significant burden on the healthcare systems and hence early and correct diagnosis is not only a doctor's dream but a population health necessity. Governments and institutions are investing more in diagnostic facilities as it is realized that early detection halts disease progression, saves caregiver time and effort, and reduces long-term healthcare costs.

Restraints

Even with great technological developments, treatment access for Alzheimer's diagnostic technology is unequal and expensive especially in low- and middle-income economies. Advanced modalities like PET imaging and cerebrospinal fluid examination are technically sophisticated, personnel-skill intensive, and laboratory intensive capital not equally distributed. Even in high-income economies, diagnosis paths may be disjointed, with patients experiencing prolonged waiting times, insurance barriers, and irregular physician referral. Moreover, stigma anxiety or emotional distress causes individuals to postpone early testing. Such innovation-access lag curbs market development, particularly on the community level as well as in preventive care. Bridging close costs and infrastructure gaps is a significant barrier to reaching equitable diagnostic coverage across the world.

Opportunites

Innovations in blood-based biomarker testing is one of the most promising opportunities in the diagnosis of Alzheimer's. These minimally invasive tests, that capture precise, blood-borne proteins such as beta-amyloid and phosphorylated tau, have the potential to exponentially increase access to stage-one diagnosis. In contrast to PET scans or spinal taps, blood tests can be offered in outpatient departments, even half-time in primary care facilities so they're more scalable and affordable. A number of biotech companies are far along in trials, and early results demonstrate strong correspondence with conventional diagnostic criteria. This technology has the potential to democratize the diagnosis of Alzheimer's, particularly for low-resource environments, and has the potential to change the paradigm of diagnosis from reactive neurology to proactive screening.

Trends

One of the significant trends which is shaping the Alzheimer's diagnostics landscape is the convergence of artificial intelligence (AI) into cognitive testing platforms and neuroimaging analysis. AI is increasingly being employed to identify micro patterns in speech, motion, and brain scan that may not be perceived by the human eye allowing for earlier and more precise detection of preclinical Alzheimer's. Start-ups and large tech companies are designing AI-powered platforms capable of analysing huge volumes of data from MRI, PET, and cognitive tests within seconds, cutting diagnosis time and improving precision. This is particularly fitting in remote or poorly equipped settings, where specialist access is hindered. As AI continues to develop, its implementation in diagnostics is not displacing clinicians but complementing their capacity to provide quicker, wiser, and more standardized assessments.

Alzheimers Disease Diagnostics Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2025-2031

Market Size in 2024

US$ 5.2 billion

Market Size in 2031

US$ 9.1 billion

Market CAGR

8.1%

By Diagnostic Technique

  • Biomarkers
  • Imaging Techniques
  • Genetic Testing
  • Cognitive Assessment Tests

By Type

  • Triage
  • Diagnosis
  • Screening

By End User

  • Hospital
  • Diagnostic Laboratories
  • Academic and Research Institutes

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Analyst Review

According to PBI Analyst, the bacterial vaccines market is experiencing significant growth, driven by rising awareness of infectious disease prevention, government immunization programs, and advancements in vaccine technology. The increasing prevalence of antibiotic-resistant bacterial infections has further emphasized the need for effective vaccination strategies. Subunit/conjugate vaccines dominate the market due to their superior safety and immunogenicity, while paediatric vaccination remains the largest segment, supported by global immunization initiatives. Intramuscular administration is the most preferred route, ensuring optimal immune response. Hospital pharmacies lead in vaccine distribution due to their robust storage infrastructure. Continuous research, AI-driven vaccine development, and expanding immunization coverage are expected to fuel market expansion.

Key Features of the Report

  • The alzheimer’s disease diagnostics market report provides granular level information about the market size, country market share, historic market (2020-2024) and forecast (2025-2031)
  • The report covers in-detail insights about the competitors overview, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startups details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis

Download Free Sample Report

Frequently Asked Questions

Alzheimer’s disease diagnostics market size was valued at US$ 5.2 billion in 2024 and is projected to reach US$ 9.1 billion by 2031, growing at an 8.1%.

Government-led immunization programs and increasing awareness of bacterial disease prevention are major factors driving the bacterial vaccines market.

The growing demand for combination vaccines, offering protection against multiple bacterial infections in a single dose, is shaping market expansion.

Market research is segmented based on vaccine type, patient age group, route of administration, distribution channel and region.

Asia-Pacific is the fastest-growing region due to rising healthcare investments, expanding immunization programs, and increasing vaccine production capabilities.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Alzheimer’s Disease Diagnostics Market Introduction 
2.1.Global Alzheimer’s Disease Diagnostics Market   - Taxonomy
2.2.Global Alzheimer’s Disease Diagnostics Market   - Definitions
2.2.1.Diagnostic Technique
2.2.2.Type
2.2.3.End User
2.2.4.Region
3.Global Alzheimer’s Disease Diagnostics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Alzheimer’s Disease Diagnostics Market Analysis, 2020 - 2024 and Forecast 2025 - 2031
4.1.  Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Alzheimer’s Disease Diagnostics Market By Diagnostic Technique, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
5.1. Biomarkers
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Imaging Techniques
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Genetic Testing
5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Cognitive Assessment Tests
5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Alzheimer’s Disease Diagnostics Market By Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
6.1. Triage
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Diagnosis
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Screening
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7.Global Alzheimer’s Disease Diagnostics Market   By End User, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
7.1. Hospital
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Diagnostic Laboratories
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Academic and Research Institutes
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Alzheimer’s Disease Diagnostics Market   By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Alzheimer’s Disease Diagnostics Market  ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
9.1. Diagnostic Technique Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Biomarkers
9.1.2.Imaging Techniques
9.1.3.Genetic Testing
9.1.4.Cognitive Assessment Tests
9.2.  Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Triage
9.2.2.Diagnosis
9.2.3.Screening
9.3.  End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital
9.3.2.Diagnostic Laboratories
9.3.3.Academic and Research Institutes
9.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Alzheimer’s Disease Diagnostics Market  ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
10.1. Diagnostic Technique Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Biomarkers
10.1.2.Imaging Techniques
10.1.3.Genetic Testing
10.1.4.Cognitive Assessment Tests
10.2.  Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Triage
10.2.2.Diagnosis
10.2.3.Screening
10.3.  End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital
10.3.2.Diagnostic Laboratories
10.3.3.Academic and Research Institutes
10.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Alzheimer’s Disease Diagnostics Market  ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
11.1. Diagnostic Technique Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Biomarkers
11.1.2.Imaging Techniques
11.1.3.Genetic Testing
11.1.4.Cognitive Assessment Tests
11.2.  Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Triage
11.2.2.Diagnosis
11.2.3.Screening
11.3.  End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital
11.3.2.Diagnostic Laboratories
11.3.3.Academic and Research Institutes
11.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Alzheimer’s Disease Diagnostics Market  ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
12.1. Diagnostic Technique Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Biomarkers
12.1.2.Imaging Techniques
12.1.3.Genetic Testing
12.1.4.Cognitive Assessment Tests
12.2.  Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Triage
12.2.2.Diagnosis
12.2.3.Screening
12.3.  End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital
12.3.2.Diagnostic Laboratories
12.3.3.Academic and Research Institutes
12.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Alzheimer’s Disease Diagnostics Market  ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
13.1. Diagnostic Technique Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Biomarkers
13.1.2.Imaging Techniques
13.1.3.Genetic Testing
13.1.4.Cognitive Assessment Tests
13.2.  Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Triage
13.2.2.Diagnosis
13.2.3.Screening
13.3.  End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital
13.3.2.Diagnostic Laboratories
13.3.3.Academic and Research Institutes
13.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Quest Diagnostics
14.2.2.Labcorp
14.2.3.C2N Diagnostics
14.2.4.Fujirebio
14.2.5.Hoffmann-La Roche
14.2.6.Quanterix
14.2.7.Sysmex
14.2.8.Lantheus
14.2.9.Siemens Healthineers
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Quest Diagnostics
  • Labcorp
  • C2N Diagnostics
  • Fujirebio
  • Hoffmann-La Roche
  • Quanterix
  • Sysmex
  • Lantheus
  • Siemens Healthineers

Related Industry Reports